Maze Therapeutics: Q4 net loss $29.6M, FY net income $52.2M on $167.5M license revenue; cash runway into H2 2027

Maze Therapeutics, Inc.

2025-Q1 EPS reported -$1.15

Q4 net loss $29.6M vs $26.6M loss a year ago; FY net income $52.2M vs $100.4M loss in 2023.
Cash and cash equivalents $196.8M as of Dec 31, 2024, up from $29.2M; combined with Feb 2025 IPO proceeds of $140M provides runway into H2 2027.
License revenue of $167.5M in FY2024 primarily from $150M upfront from Shionogi for MZE001.
Phase 2 HORIZON trial of MZE829 for AKD dosing patients; initial data expected Q1 2026.
Phase 1 trial of MZE782 ongoing; initial data including proof-of-mechanism expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.